富瀚微(300613.SZ):股東傑智控股擬向東方企慧轉讓5.22%股份
格隆匯 3 月 17日丨富瀚微(300613.SZ)公佈,公司於2021年3月17日收到股東傑智控股有限公司(“傑智控股”、“轉讓方”)通知,獲悉傑智控股與西藏東方企慧投資有限公司(“東方企慧”、“受讓方”)於2021年3月17日簽署了《股份轉讓協議》,轉讓方擬向受讓方轉讓其持有的418萬股公司股份,佔公司總股本比例5.22%,轉讓價格為116.47元/股等值美元,股份轉讓價款總額為4.87億元等值美元。
此次協議轉讓的受讓方西藏東方企慧投資有限公司作為產業戰略投資者,將充分利用自身優勢為上市公司加快產業佈局整合,將有利於上市公司優化資源配置,協同合作、實現共贏發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.